Table 2 Reported management of outpatients with acute bronchiolitis in 2001 and 2006

	2001 survey (n = 422)					2006 survey (n = 498)					p Value
	Always	Sometimes	High risk	Never	Missing	Always	Sometimes	High risk	Never	Missing	p Value
Salbutamol	254	149	1	2	16	117	314	8	32	27	<0.001
	60.2	35.3	0.2	0.5	3.8	23.5	63.1	1.6	6.4	5.4
Ipratropium bromide	9	108	4	162	139	2	98	2	273	123	0.004
	2.1	25.6	1.0	38.4	32.9	0.4	19.7	0.4	54.8	24.7
Cromoglycates	10	62	1	289	60	10	37	1	405	45	0.002
	2.4	14.7	0.2	68.5	14.2	2.0	7.4	0.2	81.3	9.0
Steroids (any)	148	207	10	31	26	40	257	26	139	36	<0.001
	35.1	49.1	2.4	7.4	6.2	8.0	51.6	5.2	27.9	7.2
Inhaled	143	197	9	35	38	32	205	24	171	66	<0.001
	33.9	46.7	2.1	8.3	9.0	6.4	31.2	4.8	34.3	13.3
Systemic	14	142	13	137	116	12	163	19	238	66	0.769
	3.3	33.7	3.1	32.5	27.5	2.4	32.7	3.8	47.8	13.3
Antibiotics	6	148	75	157	36	3	85	59	302	49	<0.001
	1.4	35.1	17.8	37.2	8.5	0.6	17.1	11.9	60.6	9.8
Nasal drops (any)	189	204	0	10	19	298	169	1	8	22	<0.001
	44.8	48.3	0.0	2.0	5.0	59.8	34.0	0.0	2.0	4.4
Xylometazoline	58	268	3	38	55	135	291	2	31	39	<0.001
	13.7	63.5	0.7	9.0	13.0	27.1	58.4	0.4	6.2	7.8
NaCl 0.9%	176	169	0	12	65	278	159	1	10	50	0.001
	41.7	40.1	0.0	2.8	15.4	55.8	31.9	0.2	2.0	10.0
Physiotherapy	–	–	–	–	–	20	184	43	185	66	NA
	–	–	–	–	–	4.0	36.9	8.6	37.1	13.2

Data are presented as n (first line) and row per cent (second line) for each treatment. Data from hospital based and primary care physicians are included.
p Values are derived from Fisher’s exact test.